JPRN-jRCTs031190203已完成2 期
A Multicenter, Double-blind, Randomized Exploratory Study Assessing Efficacy of HMG-CoA Reductase Inhibitor/Cholesterol Ointment for Porokeratosis - HMG-CoA/Chol trial
Shinkuma Satoru0 个研究点目标入组 10 人开始时间: 2020年2月6日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Clinically or histopathologically diagnosed with porokeratosis
- •More than two lesions or have a lesion of at lease 10cm in diameter
- •Obtained consent
排除标准
- •Patients with contraindications to atorvastatin use
研究者
相似试验
招募中
2 期
A clinical trial to know the abnormal respone of cortisol secretion following topical clobetasol propionate cream application in patients with psoriasisCTRI/2012/03/002520Dr Reddys Laboratories90
进行中（未招募）
不适用
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients with SchizophreniaMedDRA version: 14.1Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersSchizophreniaEUCTR2011-004889-15-DEJanssen-Cilag International N.V.1,388
进行中（未招募）
不适用
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients with SchizophreniaSchizophreniaEUCTR2011-004889-15-SEJanssen-Cilag International N.V.1,288
进行中（未招募）
不适用
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients with SchizophreniaMedDRA version: 14.1Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersSchizophreniaEUCTR2011-004889-15-FIJanssen-Cilag International N.V.1,288
进行中（未招募）
不适用
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients with SchizophreniaMedDRA version: 14.1Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersSchizophreniaEUCTR2011-004889-15-ESJanssen-Cilag International N.V.1,288